ATL 1102

Drug Profile

ATL 1102

Alternative Names: ATL-1102; ATL/TV-1102; ISIS-107248; TV-1102

Latest Information Update: 16 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Antisense Therapeutics; Childrens Hospital Los Angeles
  • Class Anti-inflammatories; Antirheumatics; Antisense oligonucleotides
  • Mechanism of Action Integrin alpha4 inhibitors; Integrin alpha4beta1 antagonists; RNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Asthma; Multiple sclerosis

Highest Development Phases

  • Phase II Multiple sclerosis
  • Preclinical Asthma; Cancer
  • Discontinued Stem cell mobilisation; Vertigo

Most Recent Events

  • 15 Feb 2016 Antisense intends to file an IND application with the US FDA for Multiple sclerosis
  • 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
  • 08 Dec 2015 Antisense files for patent protection for ATL 1102
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top